<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="4B31B0FA-3D68-40CA-2BA8-786AA182EDAE" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Human Prescription Drug Label" />
<title mediaType="text/x-hl7-title+xml">ERYTHROMYCIN ETHYLSUCCINATE TABLETS, USP</title>
<effectiveTime value="20060531" />
<setId root="4B31B0FA-3D68-40CA-2BA8-786AA182EDAE" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Abbott Laboratories</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="647CC6F0-B0B3-FB50-883E-0B275F2A1781" />
<effectiveTime value="20060531" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0074-2589" codeSystem="2.16.840.1.113883.6.69" />
<name>Erythromycin Ethylsuccinate</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" codeSystemName="FDA DRG 201" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="400">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="400" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="1014KSJ86F" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Erythromycin ethylsuccinate</name>
<activeMoiety>
<activeMoiety>
<code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Erythromycin</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>erythromycin ethylsuccinate</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Confectioner's sugar</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Red No. 40</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>magnesium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>polacrilin potassium</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium citrate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0074-2589-13" codeSystem="2.16.840.1.113883.6.69" codeSystemName="NDC" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="500">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="500" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0074-2589-53" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="1" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">74;ZE</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="19" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="9147DAD2-4EA2-6EF9-96ED-C0769746DD90" />
<text><paragraph>To reduce the development of drug-resistant bacteria
and maintain the effectiveness of erythromycin ethylsuccinate tablets and
other antibacterial drugs, erythromycin ethylsuccinate tablets should be used
only to treat or prevent infections that are proven or strongly suspected
to be caused by bacteria.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="64F4015F-F810-7252-4985-F2F59353903D" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION section" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>Erythromycin is produced by a strain of <content styleCode="italics">Saccharopolyspora
erythraea</content> (formerly <content styleCode="italics">Streptomyces erythraeus</content>) and belongs to the macrolide group of antibiotics.  It is basic
and readily forms salts with acids.  The base, the stearate salt, and the
esters are poorly soluble in water.  Erythromycin ethylsuccinate is an ester
of erythromycin suitable for oral administration.  Erythromycin ethylsuccinate
is known chemically as erythromycin 2'-(ethylsuccinate).</paragraph><paragraph>Erythromycin ethylsuccinate tablets for oral administration
are intended primarily for adults or older children.  Each tablet contains
erythromycin ethylsuccinate equivalent to 400 mg of erythromycin activity.
 The molecular formula is C<sub>43</sub>H<sub>75</sub>NO<sub>16</sub> and
the molecular weight is 862.06.  The structural formula is:</paragraph><paragraph><renderMultiMedia referencedObject="MM1133373456-1" /></paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="B86E810F-81E7-9159-BF08-D0C264E81C1A" />
<title mediaType="text/x-hl7-title+xml">Inactive Ingredients</title>
<text><paragraph>Confectioner's sugar (contains corn starch),
corn starch, FD&amp;C Red No. 40, magnesium stearate, polacrilin potassium
and sodium citrate.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<observationMedia ID="MM1133373456-1">
<id root="CAFF7265-71A4-4BCE-C0AD-E0DFD8B3A2DA" />
<value mediaType="image/jpeg" xsi:type="ED"><reference value="erythromycin-ethylsuccinate-tablets-structure.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section>
<id root="A05E989A-A9E7-F019-4B70-767093AAA8E0" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY section" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph>Orally administered erythromycin ethylsuccinate tablets
are readily and reliably absorbed under both fasting and nonfasting conditions.</paragraph><paragraph>Erythromycin diffuses readily into most body fluids.  Only
low concentrations are normally achieved in the spinal fluid, but passage
of the drug across the blood-brain barrier increases in meningitis.  In the
presence of normal hepatic function, erythromycin is concentrated in the liver
and excreted in the bile; the effect of hepatic dysfunction on excretion of
erythromycin by the liver into the bile is not known.  Less than 5 percent
of the orally administered dose of erythromycin is excreted in active form
in the urine.</paragraph><paragraph>Erythromycin crosses the placental
barrier, but fetal plasma levels are low.  The drug is excreted in human milk.</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="D7E41168-7B1F-8B6F-1C71-D33D86FE6A97" />
<title mediaType="text/x-hl7-title+xml">Microbiology</title>
<text><paragraph>Erythromycin acts by inhibition of protein synthesis by binding
50 <content styleCode="italics">S</content> ribosomal subunits of susceptible
organisms.  It does not affect nucleic acid synthesis.  Antagonism has been
demonstrated <content styleCode="italics">in vitro</content> between erythromycin
and clindamycin, lincomycin, and chloramphenicol.</paragraph><paragraph>Many
strains of <content styleCode="italics">Haemophilus influenzae  </content> are
resistant to erythromycin alone but are susceptible to erythromycin and sulfonamides
used concomitantly.</paragraph><paragraph>Staphylococci resistant to
erythromycin may emerge during a course of therapy.</paragraph><paragraph>Erythromycin
has been shown to be active against most strains of the following microorganisms,
both <content styleCode="italics">in vitro  </content> and in clinical infections
as described in the <content styleCode="bold">INDICATIONS AND USAGE</content> section.</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="99E76795-8462-967A-AA1E-EE5A6190685E" />
<title mediaType="text/x-hl7-title+xml">Gram-positive organisms</title>
<text><paragraph><content styleCode="italics">Corynebacterium
diphtheriae</content></paragraph><paragraph><content styleCode="italics">Corynebacterium minutissimum</content></paragraph><paragraph><content styleCode="italics">Listeria monocytogenes</content></paragraph><paragraph><content styleCode="italics">Staphylococcus
aureus</content> (resistant organisms may emerge during treatment)</paragraph><paragraph><content styleCode="italics">Streptococcus pneumoniae</content></paragraph><paragraph><content styleCode="italics">Streptococcus
pyogenes</content></paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="3EEDBE97-0840-01F1-22A5-09129CB99602" />
<title mediaType="text/x-hl7-title+xml">Gram-negative organisms</title>
<text><paragraph><content styleCode="italics">Bordetella
pertussis</content></paragraph><paragraph><content styleCode="italics">Legionella pneumophila</content></paragraph><paragraph><content styleCode="italics">Neisseria gonorrhoeae</content></paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="54D81CDE-9230-F806-BD18-9571241D8BC9" />
<title mediaType="text/x-hl7-title+xml">Other microorganisms</title>
<text><paragraph><content styleCode="italics">Chlamydia
trachomatis</content></paragraph><paragraph><content styleCode="italics">Entamoeba histolytica</content></paragraph><paragraph><content styleCode="italics">Mycoplasma
pneumoniae</content></paragraph><paragraph><content styleCode="italics">Treponema pallidum</content></paragraph><paragraph><content styleCode="italics">Ureaplasma urealyticum</content></paragraph><paragraph>The following <content styleCode="italics">in vitro</content> data are available, <content styleCode="bold"><content styleCode="underline">but their clinical significance is unknown</content></content>.</paragraph><paragraph>Erythromycin exhibits <content styleCode="italics">in vitro </content> minimal inhibitory concentrations
(MIC's) of 0.5 mcg/mL or less against most (&#8805; 90%) strains of
the following microorganisms; however, the safety and effectiveness of erythromycin
in treating clinical infections due to these microorganisms have not been
established in adequate and well-controlled clinical trials.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="6FBFEBE3-0D20-9B08-8791-4B61E7E55FDE" />
<title mediaType="text/x-hl7-title+xml">Gram-positive organisms</title>
<text><paragraph>Viridans group streptococci</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="472E44A1-B9ED-B324-49C4-DF31A0F855AF" />
<title mediaType="text/x-hl7-title+xml">Gram-negative organisms</title>
<text><paragraph><content styleCode="italics">Moraxella
catarrhalis</content></paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="9B790F1A-7344-27C4-E3AD-18145ECEECD3" />
<title mediaType="text/x-hl7-title+xml">Susceptibility Tests</title>
<text><paragraph /></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="614EA03F-9D50-6182-7DA1-8A8BF46A626C" />
<title mediaType="text/x-hl7-title+xml">Dilution Techniques</title>
<text><paragraph>Quantitative methods are used to determine antimicrobial
minimum inhibitory concentrations (MIC's).  These MIC's provide
estimates of the susceptibility of bacteria to antimicrobial compounds.  The
MIC's should be determined using a standardized procedure.  Standardized
procedures are based on a dilution method<sup>1</sup> (broth or agar) or equivalent
with standardized inoculum concentrations and standardized concentrations
of erythromycin powder.  The MIC values should be interpreted according to
the following criteria:</paragraph><table ID="table_1" width="100%"><colgroup align="center">
<col width="48%" />
<col width="50%" />
</colgroup>
<thead>
<tr><td><content styleCode="bold">MIC (mcg/mL)</content></td><td><content styleCode="bold">Interpretation </content></td></tr>
</thead>
<tbody>
<tr><td>&#8804;&#160;0.5</td><td>Susceptible (S)</td></tr>
<tr><td>1-4</td><td>Intermediate (I)</td></tr>
<tr><td>&#8805;&#160;8</td><td>Resistant (R)</td></tr>
</tbody>
</table><paragraph>A report of "Susceptible" indicates that the
pathogen is likely to be inhibited if the antimicrobial compound in the blood
reaches the concentrations usually achievable.  A&#160;report of "Intermediate"
indicates that the result should be considered equivocal, and, if&#160;the
microorganism is not fully susceptible to alternative, clinically feasible
drugs, the test should be repeated.  This category implies possible clinical
applicability in body sites where the drug is physiologically concentrated
or in situations where high dosage of drug can be used.  This category also
provides a buffer zone which prevents small uncontrolled technical factors
from causing major discrepancies in interpretation.  A&#160;report of "Resistant"
indicates that the pathogen is not likely to be inhibited if the antimicrobial
compound in the blood reaches the concentrations usually achievable; other
therapy should be selected.</paragraph><paragraph>Standardized
susceptibility test procedures require the use of laboratory control microorganisms
to control the technical aspects of the laboratory procedures.  Standard erythromycin
powder should provide the following MIC values:</paragraph><table ID="table_2" width="100%"><colgroup align="center">
<col width="48%" />
<col width="50%" />
</colgroup>
<thead>
<tr><td><content styleCode="bold">Microorganism</content></td><td><content styleCode="bold">MIC (mcg/mL) </content></td></tr>
</thead>
<tbody>
<tr><td><content styleCode="italics">S. aureus</content> ATCC
29213</td><td>0.12-0.5</td></tr>
<tr><td><content styleCode="italics">E. faecalis</content> ATCC
29212</td><td>1-4</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="89D92DB5-896B-B071-5300-1968E6535DC1" />
<title mediaType="text/x-hl7-title+xml">Diffusion Techniques</title>
<text><paragraph>Quantitative methods that require measurement
of zone diameters also provide reproducible estimates of the susceptibility
of bacteria to antimicrobial compounds.  One&#160;such standardized procedure<sup>2</sup> requires
the use of standardized inoculum concentrations.  This procedure uses paper
disks impregnated with 15-mcg erythromycin to test the susceptibility of microorganisms
to erythromycin.</paragraph><paragraph>Reports from the laboratory
providing results of the standard single-disk susceptibility test with a 15-mcg
erythromycin disk should be interpreted according to the following criteria:</paragraph><table ID="table_3" width="100%"><colgroup align="center">
<col width="49%" />
<col width="49%" />
</colgroup>
<thead>
<tr><td><content styleCode="bold">Zone Diameter (mm)</content></td><td><content styleCode="bold">Interpretation </content></td></tr>
</thead>
<tbody>
<tr><td>&#8805;&#160;23</td><td>Susceptible (S)</td></tr>
<tr><td>14-22</td><td>Intermediate (I)</td></tr>
<tr><td>&#8804;&#160;13</td><td>Resistant (R)</td></tr>
</tbody>
</table><paragraph>Interpretation should be as stated above for
results using dilution techniques. Interpretation involves correlation of
the diameter obtained in the disk test with the MIC&#160;for erythromycin.</paragraph><paragraph>As with standardized dilution techniques, diffusion
methods require the use of laboratory control microorganisms that are used
to control the technical aspects of the laboratory procedures.  For the diffusion
technique, the 15-mcg erythromycin disk should provide the following zone
diameters in these laboratory test quality control strains:</paragraph><table ID="table_4" width="100%"><colgroup align="center">
<col width="48%" />
<col width="50%" />
</colgroup>
<thead>
<tr><td><content styleCode="bold">Microorganism</content></td><td><content styleCode="bold">Zone Diameter (mm)</content></td></tr>
</thead>
<tbody>
<tr><td><content styleCode="italics">S. aureus</content> ATCC
25923</td><td>22-30</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="809B5A5F-1099-56C6-AEDA-13B75C6A2321" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE section" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>To reduce the development of drug-resistant bacteria
and maintain the effectiveness of erythromycin ethylsuccinate tablets and
other antibacterial drugs, erythromycin ethylsuccinate tablets should be used
only to treat or prevent infections that are proven or strongly suspected
to be caused by susceptible bacteria.  When culture and susceptibility information
are available, they should be considered in selecting or modifying antibacterial
therapy.  In the absence of such data, local epidemiology and susceptibility
patterns may contribute to the empiric selection of therapy.</paragraph><paragraph>Erythromycin ethylsuccinate tablets are indicated in the treatment
of infections caused by susceptible strains of the designated organisms in
the diseases listed below:</paragraph><paragraph>Upper respiratory
tract infections of mild to moderate degree caused by <content styleCode="italics">Streptococcus
pyogenes</content>, <content styleCode="italics">Streptococcus pneumoniae </content>, or <content styleCode="italics">Haemophilus influenzae</content> (when
used concomitantly with adequate doses of sulfonamides, since many strains
of <content styleCode="italics">H. influenzae</content> are not susceptible
to the erythromycin concentrations ordinarily achieved). (See&#160;appropriate
sulfonamide labeling for prescribing information.)</paragraph><paragraph>Lower-respiratory
tract infections of mild to moderate severity caused by <content styleCode="italics">Streptococcus
pneumoniae</content> or <content styleCode="italics">Streptococcus pyogenes </content>.</paragraph><paragraph>Listeriosis caused by <content styleCode="italics">Listeria
monocytogenes</content>.</paragraph><paragraph>Pertussis (whooping
cough) caused by <content styleCode="italics">Bordetella pertussis</content>.
 Erythromycin is effective in eliminating the organism from the nasopharynx
of infected individuals rendering them noninfectious.  Some clinical studies
suggest that erythromycin may be helpful in the prophylaxis of pertussis in
exposed susceptible individuals.</paragraph><paragraph>Respiratory
tract infections due to <content styleCode="italics">Mycoplasma pneumoniae </content>.</paragraph><paragraph>Skin and skin structure infections
of mild to moderate severity caused by <content styleCode="italics">Streptococcus
pyogenes</content> or <content styleCode="italics">Staphylococcus aureus</content> (resistant
staphylococci may emerge during treatment).</paragraph><paragraph>Diphtheria:
 Infections due to <content styleCode="italics">Corynebacterium diphtheriae </content>, as an adjunct to antitoxin, to prevent establishment of carriers
and to eradicate the organism in carriers.</paragraph><paragraph>Erythrasma:
 In the treatment of infections due to <content styleCode="italics">Corynebacterium
minutissimum</content>.</paragraph><paragraph>Intestinal amebiasis
caused by <content styleCode="italics">Entamoeba histolytica</content> (oral
erythromycins only). Extraenteric amebiasis requires treatment with other
agents.</paragraph><paragraph>Acute pelvic inflammatory disease caused
by <content styleCode="italics">Neisseria gonorrhoeae:</content> As an alternative
drug in treatment of acute pelvic inflammatory disease caused by <content styleCode="italics">N.&#160;gonorrhoeae</content> in female patients with
a history of sensitivity to penicillin.  Patients should have a serologic
test for syphilis before receiving erythromycin as treatment of gonorrhea
and a follow-up serologic test for syphilis after 3 months.</paragraph><paragraph>Syphilis Caused by <content styleCode="italics">Treponema Pallidum </content>:  Erythromycin is an alternate choice of treatment for primary
syphilis in penicillin-allergic patients.  In primary syphilis, spinal fluid
examinations should be done before treatment and as part of follow-up after
therapy.</paragraph><paragraph>Erythromycins are indicated for the
treatment of the following infections caused by <content styleCode="italics">Chlamydia
trachomatis:</content> Conjunctivitis of the newborn, pneumonia of infancy,
and urogenital infections during pregnancy.  When tetracyclines are contraindicated
or not tolerated, erythromycin is indicated for the treatment of uncomplicated
urethral, endocervical, or rectal infections in adults due to <content styleCode="italics">Chlamydia
trachomatis</content>.</paragraph><paragraph>When tetracyclines are
contraindicated or not tolerated, erythromycin is indicated for the treatment
of nongonococcal urethritis caused by <content styleCode="italics">Ureaplasma
urealyticum</content>.</paragraph><paragraph>Legionnaires' Disease
caused by <content styleCode="italics">Legionella pneumophila</content>. 
Although no controlled clinical efficacy studies have been conducted, <content styleCode="italics">in vitro</content> and limited preliminary clinical data
suggest that erythromycin may be effective in treating Legionnaires'
Disease.</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="0E103B32-B1E7-509A-8AD3-4616D3FBF52C" />
<title mediaType="text/x-hl7-title+xml">Prophylaxis</title>
<text><paragraph /></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="C6585EFB-53EA-BEC4-D9E8-8ABB9F8E9CC5" />
<title mediaType="text/x-hl7-title+xml">Prevention of Initial Attacks of Rheumatic Fever</title>
<text><paragraph>Penicillin is considered by the American Heart
Association to be the drug of choice in the prevention of initial attacks
of rheumatic fever (treatment of <content styleCode="italics">Streptococcus
pyogenes</content> infections of the upper respiratory tract, e.g., tonsillitis
or pharyngitis).  Erythromycin is indicated for the treatment of penicillin-allergic
patients.<sup>3</sup>  The therapeutic dose should be administered for 10
days.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="CFDC2B92-E783-5C68-3CC1-822700ED4087" />
<title mediaType="text/x-hl7-title+xml">Prevention of Recurrent Attacks of Rheumatic Fever</title>
<text><paragraph>Penicillin or sulfonamides are considered by the
American Heart Association to be the drugs of choice in the prevention of
recurrent attacks of rheumatic fever.  In patients who are allergic to penicillin
and sulfonamides, oral erythromycin is recommended by the American Heart Association
in the long-term prophylaxis of streptococcal pharyngitis (for the prevention
of recurrent attacks of rheumatic fever).<sup>3</sup></paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="C3DB7949-7409-1AC6-08B1-0A1C3B390B52" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS section" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>Erythromycin is contraindicated in patients with known
hypersensitivity to this antibiotic.</paragraph><paragraph>Erythromycin
is contraindicated in patients taking terfenadine, astemizole, pimozide, or
cisapride. (See <content styleCode="bold">PRECAUTIONS - Drug Interactions </content>.)</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="BAC64200-9D2B-C0CB-EC82-1C1E694E6F21" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS section" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph>There have been reports of hepatic dysfunction, including
increased liver enzymes, and hepatocellular and/or chloestatic hepatitis,
with or without jaundice, occurring in patients receiving oral erythromycin
products.</paragraph><paragraph>There have been reports suggesting
that erythromycin does not reach the fetus in adequate concentration to prevent
congenital syphilis.  Infants born to women treated during pregnancy with
oral erythromycin for early syphilis should be treated with an appropriate
penicillin regimen.</paragraph><paragraph><content styleCode="bold">Pseudomembranous
colitis has been reported with nearly all antibacterial agents, including
erythromycin, and may range in severity from mild to life threatening. Therefore,
it is important to consider this diagnosis in patients who present with diarrhea
subsequent to the administration of antibacterial agents.</content></paragraph><paragraph>Treatment with antibacterial agents alters the normal flora
of the colon and may permit overgrowth of clostridia.  Studies indicate that
a toxin produced by <content styleCode="italics">Clostridium difficile</content> is
a primary cause of "antibiotic-associated colitis".</paragraph><paragraph>After
the diagnosis of pseudomembranous colitis has been established, therapeutic
measures should be initiated.  Mild cases of pseudomembranous colitis usually
respond to discontinuation of the drug alone.  In moderate to severe cases,
consideration should be given to management with fluids and electrolytes,
protein supplementation, and treatment with an antibacterial drug clinically
effective against <content styleCode="italics">Clostridium difficile</content> colitis.</paragraph><paragraph>Rhabdomyolysis with or without renal impairment has been reported
in seriously ill patients receiving erythromycin concomitantly with lovastatin.
 Therefore, patients receiving concomitant lovastatin and erythromycin should
be carefully monitored for creatine kinase (CK) and serum transaminase levels.
 (See package insert for lovastatin.)</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="EEBFD8AD-6481-A7D8-33A5-13E11EBE7D42" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Precautions" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text />
<effectiveTime value="20060531" />
<component>
<section>
<id root="9A747C75-2E57-9D9D-F0D0-3112B9B35A6D" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS section" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph>Prescribing erythromycin ethylsuccinate tablets
in the absence of a proven or strongly suspected bacterial infection or a
prophylactic indication is unlikely to provide benefit to the patient and
increases the risk of the development of drug-resistant bacteria.</paragraph><paragraph>Since erythromycin is principally excreted by the liver,
caution should be exercised when erythromycin is administered to patients
with impaired hepatic function.  (See&#160;<content styleCode="bold">CLINICAL
PHARMACOLOGY</content> and <content styleCode="bold">WARNINGS</content> sections.)</paragraph><paragraph>There have been reports that erythromycin may aggravate
the weakness of patients with myasthenia gravis.</paragraph><paragraph>There
have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring
in infants following erythromycin therapy.  In one cohort of 157 newborns
who were given erythromycin for pertussis prophylaxis, seven neonates (5%)
developed symptoms of non-bilious vomiting or irritability with feeding and
were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy.
 A possible dose-response effect was described with an absolute risk of IHPS
of 5.1% for infants who took erythromycin for 8-14 days and 10% for infants
who took erythromycin for 15-21 days.<sup>4</sup>  Since erythromycin may
be used in the treatment of conditions in infants which are associated with
significant mortality or morbidity (such as pertussis or neonatal Chlamydia
trachomatis infections), the benefit of erythromycin therapy needs to be weighed
against the potential risk of developing IHPS.  Parents should be informed
to contact their physician if vomiting or irritability with feeding occurs.</paragraph><paragraph>Prolonged or repeated use of erythromycin may result in
an overgrowth of nonsusceptible bacteria or fungi.  If superinfection occurs,
erythromycin should be discontinued and appropriate therapy instituted.</paragraph><paragraph>When indicated, incision and drainage or other surgical
procedures should be performed in conjunction with antibiotic therapy.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="77EFFBD5-C956-BC0F-E9F1-C88E8F3CF5D2" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Information for Patients section" />
<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
<text><paragraph>Patients should be counseled that antibacterial
drugs including erythromycin ethylsuccinate tablets should only be used to
treat bacterial infections.  They do not treat viral infections (e.g., the
common cold).  When erythromycin ethylsuccinate tablets is prescribed to treat
a bacterial infection, patients should be told that although it is common
to feel better early in the course of therapy, the medication should be taken
exactly as directed.  Skipping doses or not completing the full course of
therapy may (1) decrease the effectiveness of the immediate treatment and
(2) increase the likelihood that bacteria will develop resistance and will
not be treatable by erythromycin ethylsuccinate tablets or other antibacterial
drugs in the future.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="F3F6312A-7DB7-B147-D07B-1FDE2E7D290C" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Interactions section" />
<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text><paragraph>Erythromycin use in patients who are receiving high
doses of theophylline may be associated with an increase in serum theophylline
levels and potential theophylline toxicity.  In case of theophylline toxicity
and/or elevated serum theophylline levels, the dose of theophylline should
be reduced while the patient is receiving concomitant erythromycin therapy.</paragraph><paragraph>Concomitant administration of erythromycin and digoxin has
been reported to result in elevated digoxin serum levels.</paragraph><paragraph>There have been reports of increased anticoagulant effects
when erythromycin and oral anticoagulants were used concomitantly.  Increased
anticoagulation effects due to interactions of erythromycin with various oral
anticoagulants may be more pronounced in the elderly.</paragraph><paragraph>Erythromycin
is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome
p450 enzyme system (CYP3A).  Coadministration of erythromycin and a drug primarily
metabolized by CYP3A may be associated with elevations in drug concentrations
that could increase or prolong both the therapeutic and adverse effects of
the concomitant drug.  Dosage adjustments may be considered, and when possible,
serum concentrations of drugs primarily metabolized by CYP3A should be monitored
closely in patients concurrently receiving erythromycin.</paragraph><paragraph>The following are examples of some clinically significant CYP3A
based drug interactions.  Interactions with other drugs metabolized by the
CYP3A isoform are also possible.  The following CYP3A based drug interactions
have been observed with erythromycin products in post-marketing experience:</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="10E32D15-BCF1-B0F6-0C32-1C4C071FEB58" />
<title mediaType="text/x-hl7-title+xml">Ergotamine/dihydroergotamine</title>
<text><paragraph>Concurrent use of erythromycin and ergotamine
or dihydroergotamine has been associated in some patients with acute ergot
toxicity characterized by severe peripheral vasospasm and dysesthesia.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="AF6D184D-2B47-2099-ADD7-440E69EEF3C5" />
<title mediaType="text/x-hl7-title+xml">Triazolobenzodiazepines (Such as Triazolam and Alprazolam) and Related
Benzodiazepines</title>
<text><paragraph>Erythromycin has been reported to decrease the
clearance of triazolam and midazolam, and thus, may increase the pharmacologic
effect of these benzodiazepines.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="5560928A-AB14-4BA3-C3E8-F169734FFD16" />
<title mediaType="text/x-hl7-title+xml">HMG-CoA Reductase Inhibitors</title>
<text><paragraph>Erythromycin has been reported to increase concentrations
of HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin).  Rare
reports of rhabdomyolysis have been reported in patients taking these drugs
concomitantly.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="5A475B7C-718E-D8F6-4E86-88FE63AD97E7" />
<title mediaType="text/x-hl7-title+xml">Sildenafil (Viagra)</title>
<text><paragraph>Erythromycin has been reported to increase the
systemic exposure (AUC) of sildenafil. Reduction of sildenafil dosage should
be considered.  (See Viagra package insert.)</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="FD4F88C5-F9D3-E438-FE8A-EA469C24B1C1" />
<text><paragraph>There have been spontaneous or published reports of CYP3A
based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus,
alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol,
vinblastine, and bromocriptine.</paragraph><paragraph>Concomitant
administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine
is contraindicated.  (See <content styleCode="bold">CONTRAINDICATIONS </content>.)</paragraph><paragraph>In addition, there have been reports of interactions of
erythromycin with drugs not thought to be metabolized by CYP3A, including
hexobarbital, phenytoin, and valproate.</paragraph><paragraph>Erythromycin
has been reported to significantly alter the metabolism of the nonsedating
antihistamines terfenadine and astemizole when taken concomitantly.  Rare
cases of serious cardiovascular adverse events, including electrocardiographic
QT/QT<sub>c</sub> interval prolongation, cardiac arrest, torsades de pointes,
and other ventricular arrhythmias have been observed.  (See <content styleCode="bold">CONTRAINDICATIONS</content>.)  In addition, deaths have been reported rarely with concomitant
administration of terfenadine and erythromycin.</paragraph><paragraph>There
have been post-marketing reports of drug interactions when erythromycin was
coadministered with cisapride, resulting in QT prolongation, cardiac arrhythmias,
ventricular tachycardia, ventricular fibrillation, and torsades de pointes
most likely due to the inhibition of hepatic metabolism of cisapride by erythromycin.
 Fatalities have been reported.  (See <content styleCode="bold">CONTRAINDICATIONS</content>.)</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="675B5588-BB53-6FBE-BC49-8F7068DAED69" />
<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug/Laboratory Test Interactions section" />
<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Test Interactions</title>
<text><paragraph>Erythromycin interferes with the fluorometric determination
of urinary catecholamines.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="CECD236E-C506-C812-49C4-3A96F287EA4B" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Carcinogenesis, Mutagenesis, Impairment of Fertility section" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>Long-term (2-year) oral studies conducted in rats
with erythromycin ethylsuccinate and erythromycin base did not provide evidence
of tumorigenicity.  Mutagenicity studies have not been conducted.  There was
no apparent effect on male or female fertility in rats fed erythromycin (base)
at levels up to 0.25% of diet.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="849E3166-6D76-C757-119F-F6ED44089785" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy" />
<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
<text><paragraph /></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="5EF94987-A492-A26C-6A50-5C800D127F2F" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Teratogenic Effects section" />
<title mediaType="text/x-hl7-title+xml">Teratogenic Effects.</title>
<text><paragraph /></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="AEA88FF6-64AB-DE3E-A214-2038B5E0C625" />
<title mediaType="text/x-hl7-title+xml">Pregnancy Category B</title>
<text><paragraph>There is no evidence of teratogenicity or any
other adverse effect on reproduction in female rats fed erythromycin base
(up to 0.25% of diet) prior to and during mating, during gestation, and through
weaning of two successive litters.  There are, however, no adequate and well-controlled
studies in pregnant women.  Because animal reproduction studies are not always
predictive of human response, this drug should be used during pregnancy only
if clearly needed.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="59EFE6B7-781A-9D3C-A65A-86062E065F4F" />
<code code="34079-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Labor and Delivery section" />
<title mediaType="text/x-hl7-title+xml">Labor and Delivery</title>
<text><paragraph>The effect of erythromycin on labor and delivery
is unknown.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="6C3B799A-0184-6F3D-A1B0-4802E4CEE3B4" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers section" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>Erythromycin is excreted in human milk.  Caution
should be exercised when erythromycin is administered to a nursing woman.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="97B08044-1CEE-53FC-46EA-2F1C10D849F1" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pediatric Use section" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>See <content styleCode="bold">INDICATIONS AND USAGE</content> and <content styleCode="bold">DOSAGE AND ADMINISTRATION</content> sections.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="03DE6061-E8FB-A515-C0AB-C6AF726E4842" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS section" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>The most frequent side effects of oral erythromycin
preparations are gastrointestinal and are dose-related.  They include nausea,
vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic
dysfunction and/or abnormal liver function test results may occur.  (See <content styleCode="bold">WARNINGS</content> section.)</paragraph><paragraph>Onset
of pseudomembranous colitis symptoms may occur during or after antibacterial
treatment.  (See <content styleCode="bold">WARNINGS</content>.)</paragraph><paragraph>Rarely, erythromycin has been associated with the production
of ventricular arrhythmias, including ventricular tachycardia and torsades
de pointes, in individuals with prolonged QT intervals.</paragraph><paragraph>Allergic
reactions ranging from urticaria to anaphylaxis have occurred.  Skin reactions
ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome,
and toxic epidermal necrolysis have been reported rarely.</paragraph><paragraph>There have been isolated reports of reversible hearing loss occurring
chiefly in patients with renal insufficiency and in patients receiving high
doses of erythromycin.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="BC5DCAE3-31FD-B5F4-25B1-2F5C32067EF3" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE section" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>In case of overdosage, erythromycin should be discontinued.
 Overdosage should be handled with the prompt elimination of unabsorbed drug
and all other appropriate measures should be instituted.</paragraph><paragraph>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="A9B97528-0168-D7F8-D35D-EB666A908EAB" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION section" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>Erythromycin ethylsuccinate tablets may be administered
without regard to meals.  To&#160;avoid unpleasant taste, the 400 mg tablets
should not be chewed.</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="6EF900D7-5720-DF07-25C7-4797321C31E4" />
<title mediaType="text/x-hl7-title+xml">Children</title>
<text><paragraph>Age, weight, and severity of the infection are important
factors in determining the proper dosage.  In mild to moderate infections
the usual dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day
in equally divided doses every 6 hours.  For more severe infections this dosage
may be doubled.  If twice-a-day dosage is desired, one-half of the total daily
dose may be given every 12 hours.  Doses may also be given three times daily
by administering one-third of the total daily dose every 8 hours.</paragraph><paragraph>The following dosage schedule is suggested for mild to moderate
infections:</paragraph><table ID="table_5" width="100%"><colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<thead>
<tr><td><content styleCode="bold">Body Weight</content></td><td align="center"><content styleCode="bold">Total Daily Dose</content></td></tr>
</thead>
<tbody>
<tr><td>Under 10 lbs</td><td align="center">30-50 mg/kg/day<br />15-25 mg/lb/day</td></tr>
<tr><td>10 to 15 lbs</td><td align="center">200 mg</td></tr>
<tr><td>16 to 25 lbs</td><td align="center">400 mg</td></tr>
<tr><td>26 to 50 lbs</td><td align="center">800 mg</td></tr>
<tr><td>51 to 100 lbs</td><td align="center">1200 mg</td></tr>
<tr><td>over 100 lbs</td><td align="center">1600 mg</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="8C2D7870-6196-216D-5214-D9782288D3AB" />
<title mediaType="text/x-hl7-title+xml">Adults</title>
<text><paragraph>400 mg erythromycin ethylsuccinate every 6 hours
is the usual dose.  Dosage may be increased up to 4 g per day according to
the severity of the infection.  If twice-a-day dosage is desired, one-half
of the total daily dose may be given every 12 hours.  Doses may also be given
three times daily by administering one-third of the total daily dose every
8 hours.</paragraph><paragraph>For adult dosage calculation, use
a ratio of 400 mg of erythromycin activity as the ethylsuccinate to 250 mg
of erythromycin activity as the stearate, base or estolate.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="4B1204F5-051A-B244-874C-D003004F251E" />
<text><paragraph>In the treatment of streptococcal infections, a therapeutic
dosage of erythromycin ethylsuccinate should be administered for at least
10 days.  In continuous prophylaxis against recurrences of streptococcal infections
in persons with a history of rheumatic heart disease, the usual dosage is
400 mg twice a day.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="9020434A-026A-ACA3-9B91-A083F7966448" />
<title mediaType="text/x-hl7-title+xml">For Treatment of Urethritis Due to <content styleCode="italics">C.
trachomatis</content> or <content styleCode="italics">U. urealyticum</content></title>
<text><paragraph>800 mg three times a day for 7 days.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="BE407786-5AE7-86B2-3027-965D16DBA89B" />
<title mediaType="text/x-hl7-title+xml">For Treatment of Primary Syphilis</title>
<text><paragraph /></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="0C41A623-8DCD-BA62-76FF-B0CFA670528F" />
<title mediaType="text/x-hl7-title+xml">Adults</title>
<text><paragraph>48 to 64 g given in divided doses over a period
of 10 to 15 days.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="1E560023-74D6-967B-3A46-9FF9CBA834DE" />
<title mediaType="text/x-hl7-title+xml">For Intestinal Amebiasis</title>
<text><paragraph /></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="8F21C1AD-0159-2F55-B6A7-2E82B3FAD08E" />
<title mediaType="text/x-hl7-title+xml">Adults</title>
<text><paragraph>400 mg four times daily for 10 to 14 days.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="09A4B80F-16BD-E741-13B6-0460A43C025D" />
<title mediaType="text/x-hl7-title+xml">Children</title>
<text><paragraph>30 to 50 mg/kg/day in divided doses for 10 to
14 days.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="0CC96750-D878-ED93-9F36-364992741FD9" />
<title mediaType="text/x-hl7-title+xml">For Use in Pertussis</title>
<text><paragraph>Although optimal dosage and duration have not been
established, doses of erythromycin utilized in reported clinical studies were
40 to 50 mg/kg/day, given in divided doses for 5&#160;to 14 days.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="AA2A6E25-9A28-A29D-51B1-E93B47280E32" />
<title mediaType="text/x-hl7-title+xml">For Treatment of Legionnaires' Disease</title>
<text><paragraph>Although optimal doses have not been established,
doses utilized in reported clinical data were those recommended above (1.6
to 4 g daily in divided doses.)</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="3C226FF6-23B6-55E0-BCBC-7512D88A4F48" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED section" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>Erythromycin ethylsuccinate Tablets, USP, 400 mg are
supplied as mottled pink, oval tablets bearing the Code 74 ZE in bottles of
100 (<content styleCode="bold">NDC</content> 0074-2589-13) and 500&#160;(<content styleCode="bold">NDC</content> 0074-2589-53).</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section>
<id root="595C306E-CAAC-0A72-3F96-30D41D7E39F6" />
<code code="44425-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="STORAGE AND HANDLING SECTION" />
<title mediaType="text/x-hl7-title+xml">Recommended Storage</title>
<text><paragraph>Protect tablets from exposure to light and moisture.
 Store below 86&#176;F (30&#176;C).</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="C2BAA858-2BFA-CA68-4B06-4EF48D38ED46" />
<code code="34093-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="REFERENCES section" />
<title mediaType="text/x-hl7-title+xml">REFERENCE</title>
<text><list listType="ordered" styleCode="Arabic"><item>National Committee for Clinical Laboratory Standards, <content styleCode="italics">Method
for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</content>, Third Edition.  Approved Standard NCCLS Document M7-A3, Vol.
13, No. 25.  NCCLS,  Villanova ,  PA, December 1993.</item><item>National Committee for Clinical Laboratory Standards, <content styleCode="italics">Performance
Standards for Antimicrobial Disk Susceptibility Tests</content>, Fifth Edition.
 Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24.  NCCLS,  Villanova
,  PA, December 1993.</item><item>Committee on Rheumatic Fever, Endocarditis, and  Kawasaki Disease of
the Council on Cardiovascular Disease in the Young, the American Heart Association:
 Prevention of Rheumatic Fever.  <content styleCode="italics">Circulation</content>.  78(4):1082-1086, October 1988.</item><item>Honein, M.A., et. al.:  Infantile hypertrophic pyloric stenosis after
pertussis prophylaxis with erythromycin:  a case review and cohort study.
 The Lancet 1999; 354(9196):2101-5.</item></list></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section>
<id root="DA374E7E-AFAA-8C80-ED02-92533B40C0C9" />
<text><paragraph>Abbott Laboratories</paragraph><paragraph>North Chicago,
IL 60064, U.S.A.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</structuredBody>
</component>
</document>
